Related Experiment Video
Updated: Aug 21, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome
Chun-Hong Fang1, Jian-Jun Li, Rui-Tai Hui
1Department of Cardiology, Renmin Hospital, Wuhan University School of Medicine, Wuhan 430060, PR China.
Insights
Early statin administration is crucial for acute coronary syndrome patients. Statins reduce inflammatory markers rapidly, decreasing cardiovascular events and improving outcomes.
Area of Science:
- Cardiology
- Inflammation Research
- Pharmacology
Background:
- Acute coronary syndrome (ACS) affects ~1 million US patients annually, often linked to atherosclerotic plaque rupture and thrombus formation.
- Inflammation, characterized by monocytes, macrophages, and lymphocytes, is a key feature of vulnerable plaques in ACS.
- Reduced inflammatory markers like C-reactive protein correlate with decreased coronary events in ACS patients.
Purpose of the Study:
- To evaluate the rapid anti-inflammatory effects of statins in acute coronary syndrome (ACS) patients.
- To support early clinical administration of statins in ACS based on their anti-inflammatory properties.
Main Methods:
- Review of existing studies on inflammation in ACS and statin effects.
- Analysis of recent data on inflammatory marker reduction within 24 hours of statin administration in coronary artery disease patients.
Main Results:
- Statins demonstrate potent anti-inflammatory effects, reducing C-reactive protein levels.
- A single statin dose can significantly lower inflammatory markers within 24 hours post-admission.
- These pleiotropic effects of statins correlate with reduced cardiovascular events.
Conclusions:
- Statins possess significant anti-inflammatory properties, acting as potent anti-inflammatory agents.
- Early administration of statins, similar to aspirin, is recommended for patients with acute coronary syndrome.
- Prompt statin use may mitigate inflammation and reduce cardiovascular event risk in ACS.
Abstract:
It is estimated that about 1 million patients are hospitalized for acute coronary events each years in the United States. An acceptable theory is that the acute coronary syndrome is caused by rupture of the atherosclerotic plaque with superimposed thrombus, which is a complex process and involving a number of different stages. Previous studies indicated that inflammation is one of the most important features of vulnerable plaque, and occurs in most vulnerable plaque, comprised of monocytes, macrophages, and lymphocytes in both the cap and in the adventitia. This is supported by evidence that reduction in serum inflammatory marker levels, such as C-reactive protein, significantly decreased coronary events in patients with acute coronary syndrome. A large number of investigations have demonstrated that administration of statin could modify C-reactive protein concentrations with a concurrent fall in cardiovascular events. Our recent data indicated that reduction of inflammatory markers could be achieved within 24 h following a single dose of statin administration after admission in patients with coronary artery disease. Based on the available evidence and in light of the new understanding that statins have pleiotropic effects, especially as a potent anti-inflammatory agent, the statins, like aspirin, should be clinically given as early as possible in patients with acute coronary syndrome.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:27Coronary Artery Disease V: Interprofessional Care
01:26Acute Coronary Syndrome V: Nursing Management
01:26Atherosclerosis III: Management